|Price Range 12mo avg:||$2M – $2.5M|
|$/sf 12mo avg:||$318.75|
|CAP Rate 12mo avg:||7.29%|
|Lease Terms:||15yrs NNN|
|Building Size avg:||7,500 SF|
|Lot Size avg:||2.5+/- acres|
Fresenius is a global health care group with products and services for dialysis, the hospital and the medical care of patients at home.
The Fresenius Group consists of the following four business segments that are responsible for their own business operations worldwide: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed.
Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and the New York Stock Exchange (FMS)
Fresenius Medical Care is the world’s largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 2.7 million individuals worldwide. Through its network of 3,361 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatments for 286,312 patients around the globe. Fresenius Medical Care is also the world’s leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products.
|S&P Credit Rating:||BBB-|
|Moody’s Credit Rating:||Ba1|
|Annual Revenue 2014:||$15.8B|
|Annual Revenue 2013:||$14.6B|
|Revenue Growth:||↑ 8% from 2013|
|Units (Dec. 2014)||3,361|
|Average Units Volume:||$4.7M|
Yahoo! Finance: FMS News Latest Financial News for FMS
[$$] Fresenius Medical Sells Sound Inpatient Physicians for $2.15 Billion
on June 28, 2018 at 9:22 pm
Fresenius Medical Care AG said it completed the divestment of Sound Inpatient Physicians Holdings, selling the business to an investment consortium led by Summit Partners. The German company, which provides dialysis services, said the divestment will bolster its net income by about $752 million. […]
Here's Why You Should Steer Clear of Fresenius Medical Now
on June 28, 2018 at 1:30 pm
Soft segmental performance and a downbeat revenue guidance reflect Fresenius Medical's (FMS) weaknesses. […]
Is Fresenius Medical Care AG & Co KGaA (ETR:FME) A Buy At Its Current PE Ratio?
on June 21, 2018 at 6:59 am
The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market and want to better understand how you canRead More... […]
FMC takes stake in Humacyte in bet on bioengineered blood vessel
on June 11, 2018 at 1:07 pm
Germany's Fresenius Medical Care (FMC) (FMEG.DE) has agreed to take a $150 million (112.3 million pounds) stake in U.S. tissue engineering firm Humacyte Inc. and will become the exclusive distributor of the company's bioengineered blood vessels once they win approval. The world's largest provider of kidney dialysis, FMC is banking on the alliance to lead to better ways of accessing patients' blood vessels, a delicate medical procedure that is part of providing life-saving dialysis, the company said in a statement on Monday. FMC will take a 19 percent stake in the privately held company. […]
Durham’s Humacyte lands $150M from Fresenius Medical Care
on June 11, 2018 at 12:01 pm
Durham-based Humacyte has landed a $150 million equity investment from Fresenius Medical Care. According to the companies, the investment will see Fresenius (NYSE: FMS) take a 19 percent fully diluted ownership stake in Humacyte and obtain the exclusive global rights to commercialize Humacyte’s human acellular vessel Humacyl upon approval by certain health authorities. “Humacyte is at this true inflection point in the development of our blood vessel,” says Humacyte Chief Medical Officer Dr. Jeff Lawson. […]